Every Form 4 that Hutchmed (China) Limited (HCM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HCM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCM filings page.
HUTCHMED (China) Ltd director and acting CEO/CFO Cheng Chig Fung reported performance-based equity allocations under the company’s Long Term Incentive Plan. On May 20, 2026, 30,157 ordinary shares from 2024 LTIP awards and 26,307 ordinary shares from 2025 LTIP awards were allocated at a purchase price of zero. The shares are held indirectly by an LTIP trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, subject to award terms. These are compensation-related restructurings rather than open-market trades.
HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon reported compensation-related allocations under the company’s Long Term Incentive Plan. On the reported date, 7,445 ordinary shares from awards granted on August 5, 2024 and 7,644 ordinary shares from awards granted on June 9, 2025 were allocated at a purchase price of zero.
The shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, respectively, subject to the award terms. These are indirect holdings and there were no open-market buys or sells.
HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo reported new allocations under the company’s Long Term Incentive Plan. On May 20, 2026, awards linked to FY2025 performance resulted in 132,864 ordinary shares from an August 5, 2024 grant and 75,140 ordinary shares from a June 9, 2025 grant being allocated at a purchase price of zero.
These shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest, and be transferred to his personal account, in 2027 for the 2024 grant and 2028 for the 2025 grant, subject to the awards’ terms and conditions.
HUTCHMED (China) Ltd reported a Form 4 for Deputy Chief Financial Officer Lorenso Chiu showing allocations under its Long Term Incentive Plan. On May 20, 2026, a plan trustee allocated 8,863 ordinary shares from awards granted on June 9, 2025 and 5,176 ordinary shares from awards granted on August 5, 2024, both at a purchase price of zero. These shares are held indirectly by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2028 and 2027, respectively, subject to award terms. No open-market buys or sells were reported.
HUTCHMED (China) Ltd filed a Form 4 for former director Tony Shu Kam Mok showing no reportable insider transactions. The filing data list zero purchases, sales, exercises, gifts, or other equity movements, indicating no change in his reportable ownership position during the covered period.